about
DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque PsoriasisConfirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPDA Study of 3 Doses of Dextofisopam in Females With Irritable Bowel SyndromeStudy of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious PubertyA Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of AgeEfficacy and Safety of Atacicept in Systemic Lupus ErythematosusSafety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic DrugsTrial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of FibromyalgiaA Study of Oral BTD-001 in Adults With Idiopathic HypersomniaA Study Investigating the Efficacy, Safety, and PK Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe ADA Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back PainPhase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 DiabetesSafety and Efficacy of Intranasal TBS-1 Treatment of Male HypogonadismA Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of StatinsSafety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis SubjectsA 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of FesoterodineEfficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's DiseaseStudy to Assess the Effect of Long-term Treatment With GBT440 in Participants Who Have Completed Treatment in Study GBT440-031A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic DermatitisLot-to-lot Consistency of Sci-B-Vac™ in AdultsImmunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseAn Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of MigraineStudy to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring SubjectsA Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging AbnormStudy to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisA Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder
P6153
Q61894332-8B933132-98D2-44A3-8FBB-161B77D41FD5Q61914922-3FF313FD-E48D-49EB-91A8-710923F18AEFQ61918387-05A9E81E-CF01-488A-942E-53463BBD0314Q61936088-0F08141E-EF09-41A4-8AA6-F86671AAA61CQ61956104-EB8E5586-7ED1-4541-9BBE-1DB31569ADCAQ61957152-BD3E121D-8D4F-4FAA-97D3-8305A74CB16CQ61957156-D5A4AC26-9431-4944-9727-BCEFB7CAEA02Q61975190-CE04CC6A-963B-487F-9CAD-632EA8FCA8A5Q61980958-C5B3E8C2-7F08-4667-940D-C7D0BF1B5FEDQ62110396-40C1E1F1-B0FB-4387-A2CC-DAE2D38CF73EQ62811321-0DE90A3B-5E34-4C71-9F70-F4F3A34C6A7DQ62815193-2CDB8780-0C9D-43D7-B403-EE7E57433406Q63316601-8A016CCE-B508-45D2-8A76-40584B51B63BQ63321038-56338F59-B42D-4A58-B291-4C927CE65752Q63321594-887FB63F-15E2-4FCA-BCE6-8B0266B5338BQ63334933-238EE19E-1FE7-443A-B401-C43AC4BFCFBEQ63336297-D30CE59D-0980-4BB4-91C6-A9886AC7FC22Q63337614-1EFDF2DC-9950-4654-8D84-E48E2C3668A9Q63393801-16B78D89-9ED4-452E-AB8D-6756BF00340BQ63397021-20C288A6-F14A-4D00-9283-2AC7F03FC783Q63403106-16D7932E-A5AF-494F-9C5C-453641126702Q63403502-9E27ED48-4068-4496-85E4-1F85D32C8A4CQ63404357-153E552F-A1E3-43AF-BE1E-887A4C5A5DB3Q63574660-2272F195-5DEF-455E-AD86-7E09F32AEB51Q63576117-F962E63D-7C42-4153-8386-47CDB48FDF70Q63578725-A718DB52-7D73-4827-B524-DA84A3DD980BQ64150432-E64E2E24-C800-44D1-80DA-796619C6DC38Q64184613-E12D6CCC-784B-4CFB-991B-EDA7AB1C8360Q64187770-3039053D-EAF6-4B91-BA4A-1E91A2C17CCDQ64187795-F0A66B73-EAE1-4247-B3B2-07E39348C292
P6153
description
US-amerikanische Organisation
@de
organisatie uit Verenigde Staten van Amerika
@nl
other organization in Oklahoma City, United States
@en
منظمة في أوكلاهوما سيتي، أوكلاهوما، الولايات المتحدة
@ar
name
Lynn Health Science Institute
@en
type
label
Lynn Health Science Institute
@en
altLabel
LHSI
@en
prefLabel
Lynn Health Science Institute
@en
P131
P2002
lynninstitute
P213
0000 0004 0383 1598
P2427
grid.419377.f
P31
P3500
P571
1997-01-01T00:00:00Z
P625
Point (-97.581877 35.530654)